The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
One task, one interaction, one pair, experts advocate
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Launches advanced bone density systems in India & Dubai
The FDA classified LifeVac as a Class II medical device
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Subscribe To Our Newsletter & Stay Updated
